Recommendations for using TNF? antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health - 28/11/13
, Marc Ardizzone b, Laurent Arnaud c, Jérôme Avouac d, Athan Baillet e, Alexandre Belot f, Béatrice Bouvard g, Pascal Coquerelle h, Sabrina Dadoun i, Alain Diguet j, David Launay k, Danielle Lebouc l, 1, Pierre Loulergue m, Sophie Mahy n, Pascal Mestat o, Gaël Mouterde p, Benjamin Terrier q, Coralie Varoquier r, Mathieu Verdet s, Xavier Puéchal t, Jean Sibilia uon behalf of the
Club Rhumatismes et Inflammations (CRI)
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
The use of TNFα antagonists must follow specific guidelines to ensure optimal effectiveness and safety. The French Society for Rheumatology (SFR) and Task Force on Inflammatory Joint Diseases (CRI), in partnership with several French learned societies, asked the French National Authority for Health (HAS) to develop and endorse good practice guidelines for the prescription and monitoring of TNFα antagonist therapy by physicians belonging to various specialties. These guidelines were developed, then, validated by two multidisciplinary panels of experts based on an exhaustive review of the recent literature and in compliance with the methodological rules set forth by the HAS. They pertain to the initial prescription of TNFα antagonists and to a variety of clinical situations that can arise during the follow-up of patients receiving TNFα antagonists (infections, malignancies, pregnancy, vaccination, paradoxical adverse events, surgery, use in older patients, and vasculitides).
Le texte complet de cet article est disponible en PDF.Keywords : TNFα antagonist, Etanercept, Adalimumab, Infliximab, Golimumab, Certolizumab, Cancer, Infection, Vaccination, Pregnancy, Older patients, Surgery, Vasculitis, Paradoxical adverse events, Recommendations, French National Authority for Health (HAS)
Plan
| ☆ | The Good Practice Guidelines reported herein have been endorsed by the French National Authority for Health (Haute autorité de santé française, HAS). This endorsement means that the Good Practice Guidelines were developed in compliance with the procedures and methodological rules recommended by the HAS. Any challenges to the contents of the guidelines should be directed to the promoter of this work, that is, the French Society for Rheumatology (Société française de rhumatologie, SFR). |
Vol 80 - N° 6
P. 574-581 - décembre 2013 Retour au numéro
Article précédent
- Is osteoarthritis a metabolic disease?
- Jérémie Sellam, Francis Berenbaum
- Early diagnosis and management are crucial in spondyloarthritis
- Daniel Wendling, Pascal Claudepierre, Clément Prati
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?